These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 7548472)

  • 1. Schizophrenic patients with deficit syndrome have higher plasma homovanillic acid concentrations and ventricular enlargement.
    Nibuya M; Kanba S; Sekiya U; Suzuki E; Matsuo Y; Kinoshita N; Shintani F; Yagi G; Asai M
    Biol Psychiatry; 1995 Jul; 38(1):50-6. PubMed ID: 7548472
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasma homovanillic acid differences in clinical subgroups of first episode schizophrenic patients.
    Baeza I; Castro-Fornieles J; Deulofeu R; de la Serna E; Goti J; Salvà J; Bernardo M
    Psychiatry Res; 2009 Jul; 168(2):110-8. PubMed ID: 19501918
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Negative symptoms in nondeficit syndrome respond to neuroleptic treatment with changes in plasma homovanillic acid concentrations.
    Suzuki E; Kanba S; Koshikawa H; Nibuya M; Yagi G; Asai M
    J Psychiatry Neurosci; 1996 May; 21(3):167-71. PubMed ID: 8935328
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An open study of risperidone liquid in the acute phase of schizophrenia.
    Yoshimura R; Nakamura J; Shinkai K; Goto M; Yamada Y; Kaji K; Kakihara S; Ueda N; Kohara K; Ninomiya H; Egami H; Maeda H
    Hum Psychopharmacol; 2005 Jun; 20(4):243-8. PubMed ID: 15830401
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plasma HVA in psychiatric patients: longitudinal studies.
    Javaid JI; Sharma RP; Janicak PG; Davis JM
    Psychopharmacol Bull; 1990; 26(3):361-5. PubMed ID: 2274637
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Schedule for evaluation of the deficit syndrome in schizophrenia: Schedule for Deficit Syndrome (SDS) (Kirkpatrick et al.). Importance pertinence of the SDS. Introduction of the French version].
    Ribeyre JM; Dollfus S; Lesieur P; Ménard JF; Petit M
    Encephale; 1994; 20(4):413-9. PubMed ID: 7988405
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relationship of symptomatology, gender, and antipsychotic drug treatment with plasma homovanillic acid in schizophrenia.
    Zhang ZJ; Reynolds GP; Ramchand C; Peet M; Shah S
    Acta Pharmacol Sin; 2001 Jan; 22(1):76-80. PubMed ID: 11730567
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A comparison of plasma homovanillic acid in the deficit and nondeficit subtypes of schizophrenia.
    Ribeyre JM; Lesieur P; Varoquaux O; Dollfus S; Pays M; Petit M
    Biol Psychiatry; 1994 Aug; 36(4):230-6. PubMed ID: 7986887
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasma homovanillic acid levels in schizophrenic patients: correlation with negative symptoms.
    Dávila R; Zumárraga M; Basterreche N; Arrúe A; Anguiano JB
    Psychiatry Res; 2007 May; 151(1-2):163-8. PubMed ID: 17434602
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasma 3-methoxy-4-hydroxyphenylglycol and homovanillic acid measurements in deficit and nondeficit forms of schizophrenia.
    Thibaut F; Ribeyre JM; Dourmap N; Ménard JF; Dollfus S; Petit M
    Biol Psychiatry; 1998 Jan; 43(1):24-30. PubMed ID: 9442341
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reexamination of the characteristics of the deficit schizophrenia patients.
    Tiryaki A; Yazici MK; Anil AE; Kabakçi E; Karaağaoğlu E; Göğüş A
    Eur Arch Psychiatry Clin Neurosci; 2003 Oct; 253(5):221-7. PubMed ID: 14504990
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relations of clinical features, subgroups and medication to serum monoamines in schizophrenia.
    Oades RD; Klimke A; Henning U; Rao ML
    Hum Psychopharmacol; 2002 Jan; 17(1):15-27. PubMed ID: 12404703
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Alexithymia in negative symptom and non-negative symptom schizophrenia].
    Nkam I; Langlois-Thery S; Dollfus S; Petit M
    Encephale; 1997; 23(5):358-63. PubMed ID: 9453928
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasma homocysteine levels in young male patients in the exacerbation and remission phase of schizophrenia.
    Petronijević ND; Radonjić NV; Ivković MD; Marinković D; Piperski VD; Duricić BM; Paunović VR
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Dec; 32(8):1921-6. PubMed ID: 18824063
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Atypical antipsychotics and the relevance of glutamate and serotonin.
    van der Heijden FM; Tuinier S; Fekkes D; Sijben AE; Kahn RS; Verhoeven WM
    Eur Neuropsychopharmacol; 2004 May; 14(3):259-65. PubMed ID: 15056486
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Free and conjugated plasma homovanillic acid in schizophrenic patients.
    Garcia A; Galinowski A; Guicheney P; Mignot E; Loo H; Meyer P
    Biol Psychiatry; 1989 May; 26(1):87-96. PubMed ID: 2720023
    [TBL] [Abstract][Full Text] [Related]  

  • 17. First-episode neuroleptic-free schizophrenics: concentrations of monoamines and their metabolites in plasma and their correlations with clinical responses to haloperidol treatment.
    Nagaoka S; Iwamoto N; Arai H
    Biol Psychiatry; 1997 Apr; 41(8):857-64. PubMed ID: 9099412
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Cause of mortality in schizophrenic patients: prospective study of years of a cohort of 150 chronic schizophrenic patients].
    Bralet MC; Yon V; Loas G; Noisette C
    Encephale; 2000; 26(6):32-41. PubMed ID: 11217537
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interstitial cells of the white matter in the dorsolateral prefrontal cortex in deficit and nondeficit schizophrenia.
    Kirkpatrick B; Messias NC; Conley RR; Roberts RC
    J Nerv Ment Dis; 2003 Sep; 191(9):563-7. PubMed ID: 14504564
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Decreased serum levels of D-serine in patients with schizophrenia: evidence in support of the N-methyl-D-aspartate receptor hypofunction hypothesis of schizophrenia.
    Hashimoto K; Fukushima T; Shimizu E; Komatsu N; Watanabe H; Shinoda N; Nakazato M; Kumakiri C; Okada S; Hasegawa H; Imai K; Iyo M
    Arch Gen Psychiatry; 2003 Jun; 60(6):572-6. PubMed ID: 12796220
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.